December 1, 2024 — One of the more colorful nominations the U.S. president-elect has made is certainly, from our perspective, Robert F. Kennedy Jr for Secretary of Health and Human Services. Described by Donald Trump as a “radical left lunatic” earlier this year, Kennedy is now getting the nod from Trump to “go wild on health and dramatically shake […]
November 29, 2024 — “Taxes on sweetened beverages have become a litmus test in public health: if you are concerned about rapidly increasing global rates of obesity, you should favor them.” This truth telling comes from a new commentary in JAMA Pediatrics. So we are happy to acknowledge the radiant sincerity of those who believe in taxing soda. But […]
November 28, 2024 — Nope. We didn’t get our way on everything this year. But it’s not too hard to count up reasons for feeling grateful as we start this day of Thanksgiving. Of course, we have personal reasons for feeling gratitude – health, happiness, friends, family, and the privilege of serving a purpose beyond ourselves. More specifically, though, […]
November 26, 2024 — Well, this is exciting. The news just flashed across our screen that the outgoing Biden administration is proposing to open up Medicare and Medicaid to coverage for obesity meds. Chiquita Brooks-LaSure, administrator of the Centers Medicare and Medicaid Services, said: “We don’t want to see people having to wait until they have these additional diseases […]
November 24, 2024 — FDA is in a quandary about compounding of the new obesity drugs, semaglutide and tirzepatide. The U.S. President-Elect has a nominee to lead FDA with a connection to this compounding kerfuffle. Marty Makary is a surgeon and professor at the Johns Hopkins School of Medicine. He is also Chief Medical Officer for the telehealth company […]
November 22, 2024 — FDA told a Federal judge yesterday that the agency isn’t yet sure whether there’s still a shortage of tirzepatide in the U.S. The agency needs more time to think about this. So for now, we have a stalemate on compounding of both semaglutide and tirzepatide. They are still on the FDA shortage list and compounders […]
November 18, 2024 — Bálint Magyar tells us in his recent Anatomy of Post-Communist Regimes that “populism offers problem-solving without moral constraints.” As we witness unconstrained egos with pseudo-populist views about obesity, diet, and health spout their dogma, the words of Magyar ring true. Robert F. Kennedy Jr. has a simple answer for obesity: “Giving good food, three meals […]
November 16, 2024 — Research presented at ObesityWeek 2024 shines a light on a blind spot in drug labeling for persons with obesity. No, we’re not talking about the latest buzzy drug for treating obesity. Rather, we are talking about a prime example of labeling for other drugs that people with obesity may need when they face a serious […]
November 15, 2024 — If one is in the mood to stare into the abyss of futility, the Lancet has a perspective for you on obesity today. The Global Burden of Disease project has a new analysis of obesity in the U.S. It tells us that 76% of adults 25 and older have overweight and obesity. Furthermore, that number […]
November 14, 2024 — In the New England Journal of Medicine yesterday, detailed results of a three-year study showed that tirzepatide was 99% effective in preventing diabetes in people with prediabetes and obesity. This was a placebo-controlled trial. Every person in the study, whether they received tirzepatide or not, received regular lifestyle counseling. Compared to the control group getting […]
